Genmab A/S (GMAB.CO)
| Previous close | 1,799.00 |
| Open | 1,782.50 |
| Bid | 1,791.50 x N/A |
| Ask | 1,793.00 x N/A |
| Day's range | 1,777.50 - 1,817.50 |
| 52-week range | 1,751.50 - 2,814.00 |
| Volume | |
| Avg. volume | 145,566 |
| Market cap | 114.468B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | 21.60 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
COPENHAGEN, Denmark, June 26, 2024--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. With this approval, EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in the U.S. to treat this patient population. This indication is approved und
- GlobeNewswire
Transactions in Connection with Share Buy-back Program
Company Announcement COPENHAGEN, Denmark; June 24, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from June 17, 2024, to June 21, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announce
- GlobeNewswire
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 424 shares at DKK 1,025.00,2,305 shares at DKK 1,032.00,1,058 shares at DKK 1,161.00,562 shares at DKK 1,210.00,287
